#USA #Boston #Skyhawk Therapeutics #American Cancer Society #Tyler Jacks

Skyhawk Therapeutics' Chairman Receives Prestigious ACS Award

In a remarkable recognition of his contributions to cancer research, Dr. Tyler Jacks, founding chairman of the Scientific Advisory Board at Skyhawk Therapeutics, has been honored with the prestigious Medal of Honor from the American Cancer Society (ACS). This award, first instituted in 1949, acknowledges distinguished individuals for their invaluable work in advancing cancer prevention, diagnosis, treatment, and survivorship.

Dr. Tyler Jacks is not only a prominent figure at Skyhawk Therapeutics but also a pioneering researcher affiliated with the Massachusetts Institute of Technology (MIT), where he established the David H. Koch Institute for Integrative Cancer Research. His accolades stem from decades of tireless dedication to unraveling the complexities of cancer through innovative research and collaboration.

A Recognition of Dedication and Impact

Dr. Benjamin L. Ebert, MD, PhD, co-founder of Skyhawk's Scientific Advisory Board and President and CEO of Dana-Farber Cancer Institute, commended Dr. Jacks for his exceptional leadership. He stated, "Tyler Jacks is a truly extraordinary scientist and leader across many fields and organizations. His recognition from ACS is richly deserved." Dr. Ebert emphasized that Dr. Jacks has effectively guided Skyhawk’s scientific endeavors, particularly in addressing cancers and diseases that pose significant challenges to patients.

Bill Haney, Co-founder and CEO of Skyhawk, also praised Dr. Jacks, highlighting his creative approach and collaborative skills. Haney remarked, "Skyhawk's pioneering work as a leader in the RNA revolution has been transformed by Tyler's insight—his contributions are not only invaluable to Skyhawk but have also benefitted numerous firms, non-profits, and universities."

Dr. Jacks' Trailblazing Research

Dr. Jacks has been pivotal in advancing the study of human cancers using genetically engineered mouse models. These innovative models have provided critical insights into tumor development and progression, helping to improve early cancer detection tools. His lab at MIT deeply investigates the roles of key genes that influence cancer behavior, including tumor suppressors and oncogenes. Moreover, he has explored how the immune system engages with developing tumors, shedding light on cancer treatment resistance.

With over 300 scientific publications to his name, Dr. Jacks has held key leadership roles, including chair positions on the National Cancer Advisory Board and the National Cancer Institute's Board of Scientific Advisors. He has received numerous accolades, such as the AACR Outstanding Achievement Award and MIT's James R. Killian Jr. Faculty Achievement Award, further cementing his status as a leading figure in cancer research.

Academic Journey and Influence

Dr. Jacks completed his undergraduate studies with highest honors in biology from Harvard College and continued his academic journey by obtaining a doctorate from the University of California, San Francisco. There, he worked under Nobel Laureate Dr. Harold Varmus, gaining valuable insights into oncogenes and cancer growth dynamics, which would later inform his own research.

Skyhawk Therapeutics itself is pioneering a clinical-stage initiative focusing on developing small molecule therapies to modulate RNA targets essential for treating various challenging diseases. Their proprietary platform, SKYSTAR®, positions the organization at the forefront of innovation in the biotech sector.

Conclusion

The awarding of the 2026 ACS Medal of Honor to Dr. Tyler Jacks marks a significant milestone not just in his career but also highlights the ongoing battle against cancer. His work serves as an inspiration to many in the scientific community striving toward breakthroughs that will improve cancer care and patient outcomes. As Skyhawk Therapeutics continues to advance in the field of RNA therapies, Dr. Jacks' leadership and vision remain crucial to their mission of addressing unmet medical needs.

For more information on Skyhawk Therapeutics and their initiatives, visit www.skyhawktx.com.